Vital Farms Inc vs Zimmer Biomet Holdings Inc — how do they compare? Vital Farms Inc trades at $13.16 (market cap $590.45M), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 29.4× Vital Farms Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| VITL | ZBH | |
|---|---|---|
Market Cap | $590.45M | $17.36B |
Sector | Consumer Staples | Health |
52-Week High | $52.41 | $107.71 |
52-Week Low | $8.28 | $79.58 |
Enterprise Value | $593.26M | $24.40B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Trailing returns across standard periods
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →